Corvus Pharmaceuticals, Inc. (CRVS) stock
Close on Nov 17, 2026Market cap $855.51MP/E –Yield –
Earnings
Corvus Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Corvus Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 11, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | – | – | -$0.22 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026during market hours | – | – | -$0.15 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 12, 2026during market hours | – | – | -$0.15 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025during market hours | – | – | -$0.12 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025during market hours | – | – | -$0.10 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025during market hours | – | – | -$0.13 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 25, 2025during market hours | – | – | -$0.18 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024during market hours | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024during market hours | – | – | -$0.07 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 6, 2024during market hours | – | – | -$0.12 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 19, 2024during market hours | – | – | -$0.14 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023during market hours | – | – | -$0.12 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023during market hours | – | – | -$0.14 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023during market hours | – | – | -$0.17 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 28, 2023during market hours | – | – | -$0.21 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022during market hours | – | – | -$0.32 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022during market hours | – | – | -$0.18 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022during market hours | – | – | -$0.18 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 10, 2022during market hours | – | – | -$0.20 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 1, 2021during market hours | – | – | -$0.24 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 15, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 29, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 25, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 29, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Corvus Pharmaceuticals guided for has been reported
Guidance history
Every forecast Corvus Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 12, 2024 | projected cash balance | Q4 FY2024 | $38.00M – $39.00M | New |
| Nov 12, 2024 | net cash used in operating activities | FY2024 | $25.00M – $26.00M | Lowered |
| Aug 6, 2024 | net cash used in operating activities | FY2024 | $24.00M – $27.00M | Lowered |
| Aug 6, 2024 | projected cash balance | FY2024 | $31.00M – $34.00M | Raised |
| May 6, 2024 | net cash used in operating activities | FY2024 | $24.00M – $27.00M | New |
| May 6, 2024 | projected cash balance | FY2024 | $31.00M – $34.00M | Raised |
| Nov 7, 2023 | net cash used in operating activities | FY2023 | $22.00M – $23.00M | Lowered |
| Nov 7, 2023 | projected cash balance | FY2023 | $27.00M – $28.00M | Raised |
| Aug 8, 2023 | net cash used in operating activities | FY2023 | $20.00M – $22.00M | Lowered |
| Aug 8, 2023 | projected cash balance | FY2023 | $28.00M – $30.00M | Raised |
| May 8, 2023 | net cash used in operating activities | FY2023 | $19.00M – $22.00M | Lowered |
| May 8, 2023 | projected cash balance | FY2023 | $20.00M – $23.00M | Raised |
| Mar 28, 2023 | net cash used in operating activities | FY2023 | $19.00M – $22.00M | New |
| Mar 28, 2023 | projected cash balance | FY2023 | $20.00M – $23.00M | Raised |
| Nov 3, 2022 | net cash used in operating activities | FY2022 | $27.00M – $29.00M | Lowered |
| Nov 3, 2022 | projected cash balance | FY2022 | $40.50M – $42.50M | Raised |
| Aug 8, 2022 | net cash used in operating activities | FY2022 | $27.00M – $29.00M | Lowered |
| Aug 8, 2022 | projected cash balance | FY2022 | $40.50M – $42.50M | Raised |
| Mar 10, 2022 | net cash used in operating activities | FY2022 | $34.00M – $36.00M | New |
| Nov 1, 2021 | net cash used in operating activities | FY2021 | $36.00M | New |
| Nov 1, 2021 | cash, cash equivalents and marketable securities | FY2021 | $70.00M | Raised |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Corvus Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
- Results
- Results
- Update
- Results
- Results
- Results
- Update
- Update
- Results
See a number that looks wrong?